Investigating Helicobacter pylori-related pyloric hypomotility: functional, histological, and molecular alterations

Aya Aly Ashraf1, Sarah Mahmoud Gamal1, Hend Ashour1,2

  • 1Department of Medical Physiology, Faculty of Medicine, Cairo University, Giza, Egypt.

Insights

Helicobacter pylori infection reduces pyloric contractility and miR-1 expression in rats, potentially causing gastric motility disorders. Treatment improved these factors, suggesting miR-1 as a therapeutic target for H. pylori complications.

Area of Science:

  • Gastroenterology and Hepatology
  • Molecular Biology
  • Microbiology

Background:

  • Helicobacter pylori (H. pylori) infection is linked to various gastric motility disorders.
  • The precise pathogenic mechanisms, including hormonal and molecular alterations, remain incompletely understood.
  • MicroRNA-1 (miR-1) has emerged as a potential factor in smooth muscle dysfunction.

Purpose of the Study:

  • To investigate the ex vivo pyloric activity in H. pylori-infected rats.
  • To explore alterations in ghrelin hormone and pyloric fibrogenesis associated with H. pylori infection.
  • To assess the role of miR-1 in H. pylori-induced pyloric dysfunction.

Main Methods:

  • Ninety male Wistar albino rats were divided into control and various treatment groups, including H. pylori infection and antibiotic treatments.
  • Urease activity confirmed H. pylori infection.
  • Ex vivo pyloric contractility, serum ghrelin levels, histological changes, and miR-1 expression in pyloric tissue were evaluated. Epithelial to mesenchymal transition (EMT) markers (TGFβ, α-SMA, E-cadherin) were also assessed.

Main Results:

  • H. pylori infection significantly reduced pyloric contractility (P < 0.001).
  • Infected rats showed decreased miR-1 expression, reduced serum ghrelin, elevated TGFβ and α-SMA, and decreased E-cadherin.
  • Treatment with antibiotics partially or fully restored miR-1 levels and molecular markers, improving pyloric function.

Conclusions:

  • H. pylori infection is associated with reduced miR-1 expression, epithelial to mesenchymal transition (EMT), and pyloric hypomotility.
  • These molecular and functional changes may contribute to gastric motility disorders observed in H. pylori infections.
  • Targeting miR-1 presents a potential therapeutic strategy for managing H. pylori-associated pyloric dysfunction.

Related Concept Videos

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies01:28

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies

Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
241
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
655
Pathophysiology of Peptic Ulcer Disease: Injurious Factors01:22

Pathophysiology of Peptic Ulcer Disease: Injurious Factors

Peptic ulcers are sores on the stomach's inner lining and the upper small intestine, which are the result of disruptions in the mucosal layer that houses parietal cells which produce gastric acid, and chief cells which secrete pepsinogen.
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...
809
Gastric Motility01:16

Gastric Motility

Gastric motility is the coordinated contraction and relaxation of stomach muscles that convert ingested food into chyme, a semi-liquid substance ready for further digestion in the intestines. The process begins with the vagus nerve inducing the relaxation of the smooth muscles in the fundus and body of the stomach, allowing these regions to expand and accommodate up to approximately 1.5 liters of food and liquid.
Peristaltic Waves and Chyme Formation
Upon food entry, the stomach initiates...
1.5K
Imaging Studies III: Gastrointestinal Motility Studies and Virtual Colonoscopy01:26

Imaging Studies III: Gastrointestinal Motility Studies and Virtual Colonoscopy

This lesson explores three gastrointestinal imaging techniques: radionuclide testing, colonic transit studies, and virtual colonoscopy.
Radionuclide Testing
Radionuclide testing is a sophisticated medical technique for assessing gastrointestinal motility. It focuses on gastric emptying and colonic transit time. Radioactive markers track the movement of food through the digestive system, providing insights into gastrointestinal disorders.
In gastric emptying studies, a meal's liquid and...
187
Gastrointestinal Motility Disorders01:20

Gastrointestinal Motility Disorders

Gastrointestinal or GI motility disorders are characterized by irregular gastrointestinal tract movements, disrupting food transit from the mouth to the anus. They are caused by damage or dysfunction in gut muscles or nerves. These disorders can cause symptoms such as severe constipation, diarrhea, abdominal pain, and swallowing difficulties. Disorders can affect any segment of the GI tract and range widely in severity, from common conditions like GERD to life-threatening conditions like...
678